Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07283770
PHASE1
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
Sponsor: Vertex Pharmaceuticals Incorporated
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581.
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-581 in Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
128
Start Date
2025-12-09
Completion Date
2026-11-19
Last Updated
2025-12-29
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
VX-581
Suspension for Oral Administration.
DRUG
Placebo
Suspension for Oral Administration.
Locations (1)
Altasciences - Kansas City
Overland Park, Kansas, United States